PMC10198612_01
Improvement in the different headache parameters during treatment with anti-CGRP mAbs. Each point shows the value of the chosen parameter by month. MHD was reduced significantly with erenumab and fremanezumab (A), and decrease in AD and AS was significant only with the fremanezumab treatment (B, C). The amplitude of change was highest in AD among all parameters and reported to be the most impactful for the patient (D, E). (F) Illustrates the differential changes in various headache parameters in response to different treatments. The overall efficacy of anti-CGRP mAb treatments was significant for each parameter. For MHD mean difference was 4.1**** days, AD 6.2 *** hours, AS 1.9 *** (G). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (AD, average duration of headache; AS, average severity of headache; MHD, mean headache days per month).
fneur-14-1176816-g0001.jpg
PMC10198612_01_fneur-14-1176816-g0001.jpg
F1
The average duration (AD) was 12.0 +- 2.9 h and average severity (AS) was 9.0 +- 1.0 from 10 according to the visual analog scale (VAS) per occasion before the treatment (see Figures 1A-C). AD was 6.7 +- 1.8 h, and AS was 6.8 +- 1.2. All three parameters showed a statistically significant improvement compared to the baseline (Figures 1A-C). Sweden (see Figures 1A-C). She describes the reduction in the duration of headaches as the most critical factor improving her quality of life. According to the notes from her last visit to the clinic, MHD, AD, and AS are 8.9 +- 2.2 days, 4.8 +- 1.0 h, and 6.4 +- 1.0 respectively since she was on fremanezumab (see Figures 1D, E for change in headache parameters over time).